![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2022
Bowman, Simon J.; Fox, Robert; Doerner, Thomas; Mariette, Xavier; Papas, Athena; Grader-Beck, Thomas; Fisher, Benjamin A.; Barcelos, Filipe; De Vita, Salvatore; Schulze-Koops, Hendrik; Moots, Robert J.; Junge, Guido; Woznicki, Janice N.; Sopala, Monika A.; Luo, Wen-Lin und Hueber, Wolfgang
(2022):
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
In: Lancet, Bd. 399, Nr. 10320: S. 161-171
2016
Burmester, Gerd R.; Durez, Patrick; Shestakova, Galina; Genovese, Mark C.; Schulze-Koops, Hendrik; Li, Yue; Wang, Ying A.; Lewitzky, Steve; Koroleva, Irina; Berneis, Anni Agarwal; Lee, David M. und Hueber, Wolfgang
(2016):
Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.
In: Rheumatology, Bd. 55, Nr. 1: S. 49-55
2014
McInnes, Iain B.; Sieper, Joachim; Braun, Juergen; Emery, Paul; Heijde, Desiree van der; Isaacs, John D.; Dahmen, Georg; Wollenhaupt, Jürgen; Schulze-Koops, Hendrik; Kogan, Joseph; Ma, Shenglin; Schumacher, Martin M.; Bertolino, Arthur P.; Hueber, Wolfgang und Tak, Paul P.
(2014):
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
In: Annals of the rheumatic diseases, Bd. 73, Nr. 2: S. 349-356
[PDF, 950kB]